A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

NCT05576272 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: QL1706
DRUG: Carrelizumab
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Qilu Pharmaceutical Co., Ltd.